UGANDA AMONG FIVE COUNTRIES WITH HIGHEST TB TREATMENT COVERAGE-WHO

Related Articles

Hello world!

May 29, 2024

SOME KARAMOJA POLITICIANS ALLEGEDLY FRUSTRATE EMERGENCY HEALTH SERVICES, ONLY PS DR DIANA ATWINE CAN STOP THIS

December 15, 2023

CSOs CALL FOR DOMESTIC HEALTH SECURITY FINANCING AS THE WORLD RECOVERS FROM COVID19

December 14, 2023

BY RICHARD DRASIMAKU

ARUA: SATURDAY, OCTOBER 29, 2022

Uganda is one of the five countries with the highest level of treatment coverage for tuberculosis (TB), the World Health Organisation has confirmed in its latest report.

It joins China, Bangaladesh, Brazil and Zambia in that small league of countries to have registered the highest level of treatment coverage out of the 30 high TB burden Countries.

“In the midst of stalling progress, there are some successes.  26.3 million people were treated for TB between 2018 and 2021, still far short of the 40 million targets set for 2018–2022 at the UN High-Level Meeting on TB,” WHO noted.

It said the number of people provided with TB preventive treatment rebounded in 2021 to close to 2019 pre-Covid 19 pandemic levels, but the cumulative total of 12.5 million between 2018 and 2021 was still far from the target of 30 million by the end of 2022.

More positively, TB preventive treatment for people living with HIV has far surpassed the global target of 6 million in the period 2018-2022, reaching more than 10 million in only 4 years.

Seven countries – India, Nigeria, South Africa, Uganda, the United Republic of Tanzania, Zambia and Zimbabwe – collectively accounted for 82% of those started on preventive treatment in 2021.

Seven high TB burden countries in the region – Ethiopia, Kenya, Lesotho, Namibia, South Africa, the United Republic of Tanzania and Zambia- have reached or surpassed the 2020 milestone of a 20% reduction in the TB incidence rate compared with 2015.

Countries are also increasing the uptake of new tools and guidance recommended by WHO, resulting in early access to TB prevention and care and better outcomes.

The proportion of people diagnosed with TB who were initially tested with a rapid diagnostic increased from 33% in 2020 to 38% in 2021.

Also 109 countries were using all-oral longer regimens (up from 92 in 2020) for the treatment of MDR/RR-TB, and 92 were using shorter regimens (up from 65 in 2020).

There has been increased access to shorter (1–3 months) rifamycin-based regimens for TB preventive treatment.

In 2021, 185 350 people in 52 countries were reported to have been treated with rifapentine-containing regimens, up from 25 657 in 37 countries in 2020.

These were the glimmer of hope in an otherwise grim 2022 Global TB report that stated that an estimated 10.6 million people fell ill with tuberculosis (TB) in 2021, an increase of 4.5% from 2020, and 1.6 million people died from TB (including 187 000 among HIV positive people).

The burden of drug-resistant TB (DR-TB) also increased by 3% between 2020 and 2021, with 450 000 new cases of rifampicin-resistant TB (RR-TB) in 2021.

This is the first time in many years an increase has been reported in the number of people falling ill with TB and drug resistant TB.

TB services are among many others disrupted by the COVID-19 pandemic in 2021, but its impact on the TB response has been particularly severe.

Ongoing conflicts across Eastern Europe, Africa and the Middle East have further exacerbated the situation for vulnerable populations, WHO says.

“If the pandemic has taught us anything, it’s that with solidarity, determination, innovation and the equitable use of tools, we can overcome severe health threats. Let’s apply those lessons to tuberculosis. It is time to put a stop to this long-time killer. Working together, we can end TB,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

Continued challenges with providing and accessing essential TB services have meant that many people with TB were not diagnosed and treated.

The reported number of people newly diagnosed with TB fell from 7.1 million in 2019 to 5.8 million in 2020 and while there was a partial recovery to 6.4 million in 2021, but this was still well below pre-pandemic levels.

Reductions in the reported number of people diagnosed with TB suggest that the number of people with undiagnosed and untreated TB has grown, resulting first in an increased number of TB deaths and more community transmission of infection and then, with some lag-time, increased numbers of people developing TB.

The number of people provided with treatment for RR-TB and multidrug-resistant TB (MDR-TB) has also declined between 2019 and 2020. The reported number of people started on treatment for RR-TB in 2021 was 161 746, only about one in three of those in need.

The report notes a decline in global spending on essential TB services from US$6 billion in 2019 to US$5.4 billion in 2021, which is less than half of the global target of US$13 billion annually by 2022.

As in the previous 10 years, most of the funding used in 2021 (79%) was from domestic sources.

But in other low- and middle-income countries, international donor funding remains crucial with the main source being the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) where the United States is the largest contributor and also the largest bilateral donor providing close to 50% of international donor funding for TB.

The report reiterates its call for countries to put in place urgent measures to restore access to essential TB services.

It further calls for increased investments, multisectoral action to address the broader determinants that influence TB epidemics and their socioeconomic impact as well as the need for new diagnostics, drugs and vaccines.